The characteristics of a cohort who tamper with prescribed and diverted opioid medications

Journal of Substance Abuse Treatment

Volumn 58, Issue , 2015, Pages 51-61

  Larance, Briony ^a   Lintzeris, Nicholas ^b,c   Bruno, Raimondo ^d   Peacock, Amy ^d   Cama, Elena ^a   Ali, Robert ^e   Kihas, Ivana ^a   Hordern, Antonia ^a   White, Nancy ^e   Degenhardt, Louisa ^a,f,g,h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Abuse deterrent; Abuse liability; Cohort; Opioids; Pharmaceutical opioids; Tamper resistant

Indexed keywords

ALCOHOL; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CODEINE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; ILLICIT DRUG; METHADONE; MORPHINE; OPIATE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; CHRONIC PAIN; DEPRESSION; DISABILITY; FEMALE; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HUMAN; ICD-10; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; AUSTRALIA; DRUG OVERDOSE; MIDDLE AGED; PRESCRIPTION DRUG DIVERSION; PSYCHOLOGY;

ADULT; ANALGESICS, OPIOID; ANXIETY DISORDERS; AUSTRALIA; CHRONIC PAIN; DEPRESSIVE DISORDER; DRUG OVERDOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUG DIVERSION;

EID: 84941876629     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2015.06.001     Document Type: Article

References (30)

1. Belcher J., Nielsen S., Campbell G., Bruno R., Hoban B., Larance B., et al. Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. Drug and Alcohol Review 2014, 33(1):27-32.
2. Campbell G., Mattick R., Bruno R., Larance B., Nielsen S., Cohen M., et al. Cohort protocol: The Pain and Opioids IN Treatment (POINT) study. BMC Pharmacology and Toxicology 2014, 15(17). 10.1186/2050-6511-1115-1117.
3. Chen L.H., Hedegaard H., Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014, 166:1-8.
4. Cone E.J., Giordano J., Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug and Alcohol Dependence 2013, 131(1-2):100-105.
5. Darke S. Self-report among injecting drug users: A review. Drug and Alcohol Dependence 1998, 51(3):253-263.
6. Day C., Conroy E., Lowe J., Page J., Dolan K. Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health 2006, 14(3):120-125.
7. Degenhardt L., Larance B., Bruno R., Lintzeris N., Ali R., Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: The National Opioid Medications Abuse Deterrence (NOMAD) study protocol. Addiction 2015, 110(2):226-237.
8. Dwyer R., Topp L., Maher L., Power R., Hellard M., Walsh N., et al. Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug and Alcohol Dependence 2009, 100(1-2):9-16. (Epub 2008 Nov 14). 10.1016/j.drugalcdep.2008.08.016.
9. Euser A.M., Zoccali C., Jager K.J., Dekker F.W., Euser A.M., Zoccali C., et al. Cohort studies: Prospective versus retrospective. Nephron 2009, 113(3):c214-c217.
10. Gomes T., Mamdani M.M., Dhalla I.A., Cornish S., Paterson J.M., Juurlink D.N. The burden of premature opioid-related mortality. Addiction 2014, 109(9):1482-1488. 10.1111/add.12598.
11. Gossop M., Darke S., Griffiths P., Hando J., Powis B., Hall W., et al. The Severity of Dependence Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 1995, 90:607-614.
12. Havens J.R., Leukefeld C.G., DeVeaugh-Geiss A.M., Coplan P., Chilcoat H.D. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug and Alcohol Dependence 2014, 139(0):9-17. 10.1016/j.drugalcdep.2014.02.018.
13. Katz N., Dart R.C., Bailey E.J., Trudeau J., Osgood E., Paillard F. Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. The American Journal of Drug and Alcohol Abuse 2011, 37:205-217.
14. Kessler R.C., Ustun T.B. The World Mental Health (WMH) Survey Initiative version of the World Health Organization (WHO) Composite International Diagnostic Interview (CIDI). International Journal of Methods in Psychiatric Research 2004, 13(2):93-121. 10.1002/mpr.168.
15. Kroenke K., Spitzer R., Williams J.B.W. The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine 2001, 16(9):606-613.
16. Kroenke K., Spitzer R.L., Williams J.B.W., Lowe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: A systematic review. General Hospital Psychiatry 2010, 32(4):345-359.
17. Larance B., Ambekar A., Azim T., Murthy P., Panda S., Degenhardt L. The availability, diversion and injection of pharmaceutical opioids in South Asia. Drug and Alcohol Review 2011, 30(3):246-254. 10.1111/j.1465-3362.2011.00304.x.
18. Larance B., Degenhardt L., Lintzeris N., Winstock A., Mattick R. Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. Drug and Alcohol Review 2011, 30(3):236-245. 10.1111/j.1465-3362.2010.00283.x.
19. Lenton S., Dietze P., Olsen A., Wiggins N., McDonald D., Fowlie C. Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond. Drug and Alcohol Review 2014, (Epub ahead of print). 10.1111/dar.12198.
20. Madadi P., Hildebrandt D., Lauwers A.E., Koren G. Characteristics of opioid-users whose death was related to opioid-toxicity: A population-based study in Ontario, Canada. PLoS One 2013, 8(4):e60600. 10.60610.61371/journal.pone.0060600.
21. Manchikanti L., Helm S., Fellows B., Janata J.W., Pampati V., Grider J.S., et al. Opioid epidemic in the United States. Pain Physician 2012, 15(3 Suppl.):ES9-ES38.
22. Passik S.D., Hays L., Eisner N., Kirsh K.L. Characteristics of prescription drug abusers entering drug rehabilitation. Psychiatrie and Pain 2006, 20(2):5-13.
23. Prins A., Ouimette P., Kimerling R., Camerond R.P., Hugelshofer D.S., Shaw-Hegwer J., et al. The primary care PTSD screen (PC-PTSD): Development and operating characteristics. Primary Care Psychiatry 2004, 9(1):9-14. 10.1185/135525703125002360.
24. Roxburgh A., Bruno R., Larance B., Burns L. Prescription of opioid analgesics and related harms in Australia. Medical Journal of Australia 2011, 195(5):280-284.
25. Sellers E.M., Perrino P.J., Colucci S.V., Harris S.C. Attractiveness of reformulated OxyContin® tablets: Assessing comparative preferences and tampering potential. Journal of Psychopharmacology 2013, 27:808-816.
26. Severtson S.G., Bartelson B.B., Davis J.M., Muñoz A., Schneider M.F., Chilcoat H., et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. The Journal of Pain 2013, 14(10):1122-1130.
27. Spitzer R.L., Kroenke K., Williams J.B.W., Lowe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine 2006, 166(10):1092-1097.
28. Stafford J., Burns L. Australia Drug Trends 2013: Findings from the Illicit Drug Reporting System (IDRS). Australian Drug Trends Series No. 109 2014, National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
29. Tan G., Jensen M.P., Thornby J.I., Shanti B.F. Validation of the Brief Pain Inventory for chronic nonmalignant pain. The Journal of Pain 2004, 5(2):133-137.
30. Topp L., Mattick R.P. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997, 92(7):839-845.